Electra Therapeutics, Inc. - 8-K Filing

Electra Therapeutics reports Q3 2026 net loss of $23.9 million and $402.5 million in total cash following $350 million IPO. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $ETRA

Read the full article at SEC EDGAR

More Regulatory news